Are you ready for the day after the pandemic end?

While we all busy sorting problems and react to the pandemic impactable consequences, it is imperative to prepare for the day after. It was well communicated that our life will change in many aspects, and pharmaceutical companies should be sound and ready for the change. It starts with the increased usage of online data gauging and continues in changing the customer/patient habits to order online their essential medicines. Home care treatments will be on the rise when more patients are reluctant to visit hospitals because of fear from contingency, errors due to work overload, and appropriate hospitalization condition. Telemedicine will be of great need, once it develops and offers more diagnostic solutions based on advance remote technologies. The endeavour to provide an accurate diagnostic and accessible solution will distinguish the merits of the leading companies.

Another important angle will be the increase in certain diseases due to the outbreak. Unfortunately, worsening of various diseases could be expected, as patients with more advanced cancer stages will be more common due to a lack of detection and diagnosis. Critical or semi-critical surgeries that were postponed or delayed due to the pandemic will result in worsening patients’ conditions, creating more complex and less resolvable cases by every day that goes by. Patients that unfortunately didn’t perform their half a year or yearly checkup result in disease deterioration, in many cases, inquire irreversible damage. Pressure, depression, anxiety, and loneliness, wasn’t contributive factors to the overall patients’ conditions and only deteriorate patients’ situation. inhabitant natural DNA of behaviour is been ever change, as this long period of quarantine and uncertainty, had resulted in a substantial change in inhabitant day to day merits and social behaviour. The precautions actions that will apply in our day to day activities believed to be fundamental.

From the numbers of face to face meetings, to our willingness to travel and to participate in conferences or in crowded places all will result in a substantial behavioural change. consequently, the needs for depression, obesity, ADHD and home care sedation medication will be on the rise. One can expect that some of the chronic disease patients will have disease progression and will move to a more serious class of drugs. Unfortunately, Oncology medication will also be on the rise after the pandemic, where it will take a couple of years to achieve the same disease prevalence and outcome as before the pandemic. Orphan diseases which suffer somehow from a slowdown, due to lack of detection and diagnostic, believe to catch up the past of before the pandemic only in a couple of years. Leaving many patients and caregivers frustrated and helpless in their debilitating condition. Covid-19 predominantly impact innovation, due to many new drugs clinical trials that were postponed or even cancelled due to Covid-19 risk. I believe that all of the above mentioned, won’t be restored at a glance. There will be a substantial transitional period for companies and patients to observe Covid-19 vaccination efficacy and pace. After all, there are substantial challenges ahead in this bumpy and uncertain way to contain the virus and to be back to normal life. It is unfortunate to predict that Covid-19 is not the only virus that will strike humanity, and there is a high probability to face another virus-related outbreak globally. It might be somehow a reminder to all nations that a global plan for such cases needs to be established, with a global taskforce to make the world a safer place. With pre mitigated actions (i.e., controlling and handling of wild animals and hygienic codes) to be followed.

Budget to rural areas and to failed economies to uplift their standard and maintain reasonable hygiene is of an essence. One would expect that all the countries in the world will sign a mutual disclosure agreement, where they obliged to monitor and inform a global taskforce on any epidemic treat before it converts to a pandemic. Countries need to be united in the mission of saving lives and distribute their funds, knowledge, and resources towards a mutual global solution rather than individual success, as we can observe today. The pharmaceutical companies’ role will be, to act fast and rigorously to comply with the mission. I would expect a cross-border collaboration between pharmaceutical companies, diagnostic companies, technological companies, governments, physicians, and hospitals to provide a holistic solution that will cover all the abovementioned topics. It’s not easy, but also not late to make this world a better place.